Marmoset LAG-3 (LA3-M52Ha) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - His 449 (Accession # F7HXP9-1).
Predicted N-terminus: Ala 18
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 48.0 kDa. The protein migrates as 57 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Marmoset LAG-3 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Madarex LAG-3 Mab, Human IgG1 at 2 μg/mL (100 μL/well) can bind Marmoset LAG-3 (Cat. No. LA3-M52Ha) with a linear range of 10-156 ng/mL (QC tested).
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.